research Tacrolimus in Dermatology
Tacrolimus is an effective treatment for several skin conditions with fewer side effects than cyclosporine.
Search
for
Sort by
Research
600-630 / 1000+ results 
research 139 Anti-BCC efficacy of a topical hedgehog inhibitor without adverse effects in BCNS patients in a phase 2 randomized controlled trial
Topical patidegib gel effectively treats basal cell carcinoma in Gorlin syndrome patients without causing the side effects seen with oral treatments.
research Major improvement of very severe alopecia areata in patients treated with the combination of baricitinib and low doses of corticosteroids: an eight-case series
Combining baricitinib with low-dose corticosteroids significantly improved severe hair loss in eight patients.
research Systemic Tofacitinib Treatment in Pediatric Patients with Resistant Alopecia Areata
Tofacitinib is a safe treatment for hair loss in children, but long-term use may be needed for best results.
research Biologics and Small Molecule Targeted Therapies for Pediatric Alopecia Areata, Psoriasis, Atopic Dermatitis, and Hidradenitis Suppurativa in the US: A Narrative Review
Biologics and targeted therapies could improve treatment for children with certain chronic skin conditions.
research Identification of drug-specific public TCR driving severe cutaneous adverse reactions
Researchers found a specific immune receptor in patients that causes severe skin reactions to a drug.
research A Case of Idiopathic Follicular Mucinosis Treated Successfully with Cyclosporine.
Cyclosporine effectively treated a woman's stubborn skin condition.
research A Plain Language Summary on Ritlecitinib Treatment for Adults and Adolescents with Alopecia Areata
Ritlecitinib works well and is safe for treating alopecia areata.
research Baricitinib (Olumiant)
Baricitinib is effective and cost-efficient for treating severe alopecia areata in adults.
research Switching between tofacitinib and baricitinib in alopecia areata: A review of clinical response
Switching between the medications tofacitinib and baricitinib can be effective for treating hair loss in alopecia areata.
research Introduction: splintering urbanism
TSPO might help treat anxiety and depression.
research In reply
Combining pulsed prednisone with tofacitinib can lead to lasting hair regrowth in severe alopecia areata patients.
research Paclitaxel-loaded star-shaped copolymer nanoparticles for enhanced malignant melanoma chemotherapy against multidrug resistance
The new nanoparticles could improve melanoma treatment by working better than current options.
research 27 Preclinical ex vivo and in vivo evidence supporting selective inhibition of tyrosine kinase 2-dependent, IL-12-mediated signaling as a novel pharmacological strategy for alopecia areata management
Blocking TYK2 might be a new way to treat hair loss from alopecia areata.
research 186 Mechanistic insights into Ritlecitinib-mediated immunomodulation in Alopecia Areata
research ALOPECIA UNIVERSALIS TREATED WITH ORAL CYCLOSPORINE A AND PREDNISOLONE: IMMUNOLOGIC STUDIES
Oral cyclosporine A and prednisolone effectively improved alopecia universalis without side effects.
research Neoadjuvant therapy with Disitamab vedotin in treating muscle-invasive bladder cancer: A case report
Disitamab vedotin and gemcitabine effectively treated bladder cancer without major side effects.
research Permanent diffuse alopecia after haematopoietic stem cell transplantation in childhood
Some children who had stem cell transplants developed permanent hair loss, especially when treated with a drug called busulphan.
research Pooled safety and tolerability data from four placebo-controlled teriflunomide studies and extensions
Teriflunomide is safe and tolerable for treating relapsing-remitting multiple sclerosis, with manageable side effects.
research Natural phenylethanoid glycoside forsythoside A alleviates androgenetic alopecia by selectively inhibiting TRPV3 channels in mice
Forsythoside A may help treat hair loss by blocking specific channels.
research Fast clinical response with topical ruxolitinib in the management of non-segmental vitiligo detected by VISIA<sup>®</sup> analysis system
Topical ruxolitinib quickly improves non-segmental vitiligo.
research Ixekizumab shows efficacy and safety in patients who failed biweekly etanercept therapy: Analysis From UNCOVER-2, a phase 3 randomized clinical trial in psoriasis
Ixekizumab is effective and safe for patients who did not improve with etanercept treatment for psoriasis.
research Trichodysplasia of immunosuppression treated with oral valganciclovir
Oral valganciclovir improved a patient's skin condition caused by immunosuppression.
research Moniletrix. Observación de esta infrecuente displasia pilosa en dos hermanos. Reporte clínico y dermatoscópico
Monilethrix is a genetic hair disorder affecting hair shape, seen in two brothers.
research Systematic review and meta-analysis of randomised trials and cohort studies of mycophenolate mofetil in lupus nephritis
Mycophenolate mofetil is safer and more effective than cyclophosphamide for treating lupus nephritis.
research Cortexolone 17a-propionate: Preclinical profile of a new topical, skin selective, steroidal antiandrogen
Clofazimine may be effective for treating ashy dermatosis.
research Management of Cutaneous and Extracutaneous Side Effects of Smoothened Inhibitor Therapy for Advanced Basal Cell Carcinoma
The document concludes that side effects from Smoothened inhibitor drugs for skin cancer are reversible and can be managed with a team approach to maintain quality of life.
research 267 Single- and multiple-ascending dose studies of DS-2325a, a KLK5 inhibitor for the treatment of Netherton syndrome
DS-2325a is safe and well-tolerated, supporting further development for Netherton Syndrome treatment.
research Efficacy and safety of tofacitinib in pediatric patients with alopecia areata: A prospective cohort study
Tofacitinib improved hair regrowth and quality of life in children with alopecia areata, with mild side effects.
research S4890 Infliximab-Induced Synovitis, Acne, Pustulosis, Hyperostosis, Osteitis Syndrome
Infliximab can cause SAPHO syndrome, which may improve with Spesolimab and methotrexate.